Anebulo Pharmaceuticals, Inc. (ANEB)
$
1.05
+0.18 (17.14%)
Key metrics
Financial statements
Free cash flow per share
-0.1444
Market cap
43.1 Million
Price to sales ratio
0
Debt to equity
0
Current ratio
17.3411
Income quality
0.7027
Average inventory
0
ROE
-0.6778
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing and commercializing treatments for individuals facing acute cannabinoid intoxication and substance addiction. The net income ratio is 0.00 reflecting the company's profitability margin. Additionally, the income before tax ratio is 0.00 showcasing the pre-tax margin. The company reported an income before tax of -$8,484,763.00 indicating its pre-tax profitability. Furthermore, the earnings per share (EPS) is reported at -$0.25 which highlights the company's profitability on a per-share basis. The EBITDA ratio is 0.00 underscoring the company's operational efficiency. Established in 2020 and headquartered in Lakeway, Texas, Anebulo is committed to advancing its lead product candidate, ANEB-001, a small molecule cannabinoid receptor antagonist aimed at treating cannabinoid intoxication and overdose. The stock is affordable at $2.52 making it suitable for budget-conscious investors. The stock has a low average trading volume of 66,385.00 indicating lower market activity. With a market capitalization of $43,138,935.00 the company is classified as a small-cap player. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth. As Anebulo Pharmaceuticals navigates its clinical stages and prepares for market potential, its financial metrics, market positioning, and stock accessibility cater to a diverse range of investors who are interested in the biotechnology sector and its advancements.
Is Anebulo Pharmaceuticals, Inc. (ANEB) a good investment?
Investing in Anebulo Pharmaceuticals, Inc. (ANEB) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is Anebulo Pharmaceuticals, Inc. (ANEB)'s stock forecast?
Analysts predict Anebulo Pharmaceuticals, Inc. stock to fluctuate between $0.80 (low) and $3.42 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Anebulo Pharmaceuticals, Inc.'s market capitalization?
As of 2026-01-30, Anebulo Pharmaceuticals, Inc.'s market cap is $43,138,935, based on 41,084,700 outstanding shares.
How does Anebulo Pharmaceuticals, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Anebulo Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Anebulo Pharmaceuticals, Inc. (ANEB) stock?
To buy Anebulo Pharmaceuticals, Inc. (ANEB) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ANEB. Place an order (Market, Limit, etc.).
What is the best time to invest in Anebulo Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Anebulo Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$0.25 | Growth: -21.88%.
Where can I find Anebulo Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.anebulo.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Anebulo Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Anebulo Pharmaceuticals, Inc. stock?
All-time high: $7.89 (2022-02-01) | All-time low: $0.80 (2024-12-20).
What are the key trends affecting Anebulo Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
3 days ago
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced the final results of its voluntary self-tender offer to purchase 300,000 shares of its common stock, par value $0.001 per share (“Common Stock”), which expired one minute after 11:59 p.m., New York City time, on January 26, 2026. Based on the fi.
businesswire.com
5 days ago
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer.
businesswire.com
a month ago
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced that the Board of Directors has decided to commence a cash tender offer as part of its plan to “go private” in lieu of the previously announced reverse stock split at a ratio of not less than 1-for-2,500 and not greater than 1-for-7,500. Volunta.
businesswire.com
3 months ago
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates.
businesswire.com
4 months ago
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates.
businesswire.com
4 months ago
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid-induced toxicities (the “Company” or “Anebulo”), today announces the first subjects dosed in its Phase 1 single ascending dose (“SAD”) study of intravenous (IV) selonabant in healthy young adults. The study is supported by a collaborative grant from the National Institute on Drug Abuse (NIDA). First Subjec.
businesswire.com
6 months ago
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced that a Special Committee of independent directors has recommended, and its Board of Directors (the “Board”) has approved, as part of a going private transaction, a reverse stock split at a ratio of not less than 1-for-2,500 and not greater than.
businesswire.com
9 months ago
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced financial results for the three months ended March 31, 2025, and recent updates. Third Quarter Fiscal Year 2025 and Subsequent Highlights: Anebulo is prioritizing the advancement of an intravenous selonabant as a potential treatment for pediatri.
businesswire.com
a year ago
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced financial results for the three months ended December 31, 2024, and recent updates. Second Quarter Fiscal Year 2025 and Subsequent Highlights: In December 2024, Anebulo met with FDA to discuss the development of intravenous selonabant and the in.
businesswire.com
a year ago
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise.
See all news
